We are currently engaged in the preclinical development of a number of oncology product classes that we believe represent significant unmet patient needs and address potentially large markets. We are applying our mechanism-based approach to produce novel classes of highly selective small molecules. Our approach enables us to evaluate a variety of chemical, structural and other properties that can be clinically important, such as potency, delivery and safety at the preclinical stage of development.
Our preclinical discovery research programs cover several areas: DNA methyltransferase modulation, Bcl-2 modulation, novel DNA binding agents, novel taxanes and formulations, novel platinum compounds, and novel cytoprotective agents. All of these research programs involve the combined application of computer simulations and laboratory research. We are also developing and protecting new intellectual property in these areas.